Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1113289/full |
| _version_ | 1811199145151561728 |
|---|---|
| author | Sha-Sha Wang Fang Wang Zhen Zeng Fang Gao Huan-Huan Liu Hui-Na Wang Yi Hu Hai-Feng Qin |
| author_facet | Sha-Sha Wang Fang Wang Zhen Zeng Fang Gao Huan-Huan Liu Hui-Na Wang Yi Hu Hai-Feng Qin |
| author_sort | Sha-Sha Wang |
| collection | DOAJ |
| first_indexed | 2024-04-12T01:43:02Z |
| format | Article |
| id | doaj.art-9545e9ff346d4c4cb2c356cfe5395d90 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T01:43:02Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9545e9ff346d4c4cb2c356cfe5395d902022-12-22T03:53:08ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.11132891113289Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patientSha-Sha Wang0Fang Wang1Zhen Zeng2Fang Gao3Huan-Huan Liu4Hui-Na Wang5Yi Hu6Hai-Feng Qin7Department of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, ChinaDepartment of Internal Medicine, OASIS International Hospital, Beijing, ChinaDepartment of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, ChinaDepartment of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, ChinaDepartment of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, ChinaDepartment of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, ChinaDepartment of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, ChinaDepartment of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, Chinahttps://www.frontiersin.org/articles/10.3389/fonc.2022.1113289/fullRET intergenic fusionpralsetiniblung adenocarcinomanovel intergenictyrosine kinase inhibitors |
| spellingShingle | Sha-Sha Wang Fang Wang Zhen Zeng Fang Gao Huan-Huan Liu Hui-Na Wang Yi Hu Hai-Feng Qin Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient Frontiers in Oncology RET intergenic fusion pralsetinib lung adenocarcinoma novel intergenic tyrosine kinase inhibitors |
| title | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_full | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_fullStr | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_full_unstemmed | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_short | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_sort | corrigendum case report a novel intergenic mir4299 mir8070 ret fusion with ret amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| topic | RET intergenic fusion pralsetinib lung adenocarcinoma novel intergenic tyrosine kinase inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1113289/full |
| work_keys_str_mv | AT shashawang corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT fangwang corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT zhenzeng corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT fanggao corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT huanhuanliu corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT huinawang corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT yihu corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT haifengqin corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient |